CYP1A1 and pulmonary arterial hypertension: In the present paper we reported the results of a cross-sectional study aimed to evaluate whether genetic polymorphisms (biomarkers of susceptibility) for CYP1A1, EPHX and GSTM1 genes that affect PAH activation and detoxification might influence the extent of primary DNA damage (biomarker of biologically effective dose) in PAH exposed workers (n = 109) and in unexposed controls (n = 82).